Form 10-Q BIOGEN INC. For: Mar 31

Go back to Form 10-Q BIOGEN INC. For: Mar 31

Biogen (BIIB) PT Lowered to $311 at RBC Capital

April 25, 2018 7:43 AM EDT

RBC Capital lowered its price target on Biogen (NASDAQ: BIIB) to $311.00 (from $316.00) while maintaining a Sector Perform rating.

Analyst Brian Abrahams said Q1 softness stems from Spinraza and seasonality.

... More

Biogen (BIIB) PT Lowered to $375 at Oppenheimer

April 25, 2018 7:15 AM EDT

Oppenheimer lowered its price target on Biogen (NASDAQ: BIIB) to $375.00 (from $400.00) while maintaining a Outperform rating.

Analyst Jay Olson commented, "A solid 1Q update addressed investor concerns on multiple fronts with decent financial results featuring an EPS beat of $6.05 vs $5.93E consensus and... More